NCT06489015View on ClinicalTrials.gov

Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 28, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Alzheimer's Disease (AD)
Interventions
DRUG

Recombinant Human Serum Albumin

Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Mental Health Center, Shang’ai

All Listed Sponsors
lead

Protgen Ltd

INDUSTRY